
The ₹138.87 crore Hexagon Nutrition IPO entered its second day of subscription today, June 8, 2026. The issue is priced in the ₹42-₹45 per share range. As of 11:00 AM on Day 2, the IPO was subscribed 2.58 times, while the grey market premium (GMP) was reported at around ₹6.5 per share.
Investors can bid for the issue until June 9, 2026. The basis of allotment is expected to be finalised on June 10, 2026, and the company's shares are likely to be listed on the BSE and NSE on June 12, 2026.
Explore other Upcoming IPOs on BSE and NSE.
The expected IPO schedule is as follows:
|
Event |
Tentative Date |
|
IPO Opens |
June 5, 2026 |
|
IPO Closes |
June 9, 2026 |
|
Basis of Allotment |
June 10, 2026* |
|
Initiation of Refund |
June 11, 2026 |
|
Credit of Shares to Demat Account |
June 11, 2026 |
|
Listing on BSE and NSE |
June 12, 2026* |
*Note - The allotment and listing dates are tentative and may be revised
[June 8, 2026, 11:00 AM]
|
Category |
Subscription (x) |
|
Qualified Institutional Buyers (QIBs) |
0.01x |
|
Non-Institutional Investors (NIIs) |
3.27x |
|
Retail Individual Investors (RIIs) |
3.74x |
|
Total |
2.58x |
According to media reports, the Grey Market Premium (GMP) for the Hexagon Nutrition IPO stands at around ₹6.5 per share.
Established in 1993, Hexagon Nutrition Ltd. operates as a research-focused nutrition enterprise. The company specialises in creating and producing therapeutic formulations, micronutrient premixes, wellness items, and ready-to-consume food products.
Its offerings include clinical nutrition and branded wellness products (B2C), premix formulation solutions (B2B2C), and ready-to-use foods (RUFs) and micronutrient powders (MNPs).
Hexagon Nutrition recorded revenue of ₹324.9 crore and a net profit of ₹24.3 crore in FY25, a significant increase from the ₹297.7 crore and ₹12.2 crore reported in FY24. For the nine-month period ended December 31, 2025, the company achieved operational revenue of ₹267.5 crore and a profit after tax of ₹27.03 crore.
Disclaimer: This news is solely for educational purposes. The securities/investments quoted here are not recommendatory.
To read the RA disclaimer, please click here.